Spago Nanomedical AB

SPAGO · Nasdaq Stockholm · Healthcare

0.10SEK −1.0%last day

Price as of 2 October 2026

The price over the past year, with dividends: −46.2%

Performance

1 month

−12.0%

1 year

−46.2%

3 years, per year

−33.3%

5 years, per year

−56.1%

Largest fall, 3 years

−97.4%

Below the peak now

−99.6%

Volatility, 1 year

127.7%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

2.0

Dividend yield

0.0%

Return on equity

−83.0%

Net margin

−189.8%

Market value

7 m USD

Quality, value and trend

Where Spago Nanomedical stands against every Nordic stock today. 100 is best.

Quality74

Profitability and a sound balance sheet over time. Better than 74% of Nordic stocks.

Value8

The price measured against earnings, assets and cash flow. Better than 8% of Nordic stocks.

Trend14

The price development over the past year. Better than 14% of Nordic stocks.

Combined16

Quality, value and trend together. Better than 16% of Nordic stocks.

About Spago Nanomedical

Spago Nanomedical AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 6 employees.

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis